<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230925160831&amp;fc=20230708114047&amp;v=2.17.9.post6+862 93 ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed- 2&amp;utm_source =Chrome<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230925160831&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 25 日星期一 20:08:32 +0000</lastbuilddate><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> 2 型糖尿病与重度主动脉瓣狭窄患者主动脉瓣置换术前后心肌结构、收缩功能、能量学和血流变化之间的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>结论：在严重 AS 患者中，患有 T2D 的患者在 AVR 后表现出心肌 PCr/ATP、血管舒张应激 MBF 和心脏收缩功能的持续异常；AVR 有效地使未接受 AVR 的患者的心肌 PCr/ATP、血管舒张应激 MBF 和心脏收缩功能正常化。 T2D。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 25 日。doi：10.1161/CIRCULATIONAHA.122.063444。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：2 型糖尿病 (T2D) 与严重主动脉瓣狭窄 (AS) 患者主动脉瓣置换术 (AVR) 后左心室功能障碍的风险增加相关。心肌能量和心肌血流 (MBF) 的持续损害可能是这一现象的基础本研究使用磷磁共振波谱和心血管磁共振，检验了以下假设：严重 AS 和 T2D (AS-T2D) 患者的心肌能量学会受损，如磷酸肌酸与 ATP 比率 (PCr/ATP) 和血管舒张应激所反映的那样MBF 与没有 T2D 的 AS 患者（AS-noT2D）进行了比较，并且这些差异在 AVR 后仍然存在。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：招募了 95 名等待 AVR 的无冠状动脉疾病的严重 AS 患者（30 名 AS-T2D 和 65 名 AS-noT2D）（71 岁 [69, 73]；34 名女性 [37%]）。30 名人口统计学匹配的患者健康志愿者 (HV) 和 30 名无 AS 的 T2D 患者（T2D 对照）作为对照。AVR 前 1 个月和后 6 个月，心脏 PCr/ATP、腺苷应激 MBF、整体纵向应变、NT-proBNP（N 端 pro-BNP）对 AS 患者进行了 B 型利钠肽）和 6 分钟步行距离的评估。T2D 对照者在基线和 6 个月随访时进行了相同的评估。HV 进行了一次评估，未进行 6 分钟步行测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与 HV 相比，AS 患者（AS-T2D 和 AS-noT2D 组合）显示 PCr/ATP 受损（中位数[四分位距]；HV，2.15 [1.89，2.34]；AS，1.66 [1.56，1.75]；AS，1.66 [1.56，1.75]。 AVR 前的血管舒张应激 MBF（HV，2.11 mL min g [1.89，2.34]；AS，1.54 mL min g [1.41，1.66]； <i>P</i> &lt;0.0001）。在<i>AVR</i>之前，AS 组中，患者AS-T2D 的 PCr/ATP 较差（AS-noT2D，1.74 [1.62，1.86]；AS-T2D，1.44 [1.32，1.56]； <i>P</i> = 0.002）和血管舒张应激 MBF（AS-noT2D，1.67 mL min g [1.5] ， 1.84]；AS-T2D，1.25 mL min g [1.22，1.38]； <i>P</i> = 0.001）与 AS-noT2D 患者相比。在 AVR 之前，AS-T2D 患者的 PCr/ATP 也较差（AS-T2D，1.44 [1.30, 1.60]；T2D 对照，1.66 [1.56, 1.75]； <i>P</i> = 0.04）和血管扩张剂应激 MBF（AS-T2D，1.25 mL min g [1.10, 1.41]；T2D 对照，1.54 mL min g [1.41, 1.66 ]； <i>P</i> = 0.001）与基线时的 T2D 对照相比。AVR 后，AS-noT2D 患者的 PCr/ATP 正常化，而 AS-T2D 患者则没有表现出任何改善（AS-noT2D，2.11 [1.79，2.43]；AS- T2D，1.30 [1.07，1.53]； <i>P</i> = 0.0006）。AVR 后，两个 AS 组的血管扩张剂应激 MBF 均有所改善，但 AS-T2D 患者的血管扩张剂应激 MBF 仍然较低（AS-noT2D，1.80 mL min g [1.59，2.0]； AS-T2D，1.48 mL min g [1.29，1.66]； <i>P</i> = 0.03）。PCr/ATP 不再存在差异（AS-T2D，1.44 [1.30，1.60]；T2D 对照，1.51 [1.34，1.53]； <i>AVR</i>和 T2D 后 AS-T2D 患者之间的血管扩张剂应激 MBF（AS-T2D，1.48 mL min g [1.29，1.66]；T2D 对照，1.60 mL min g [1.34，1.86]； <i>P</i> = 0.82）虽然 AS-noT2D 患者的整体纵向应变、6 分钟步行距离和 NT-proBNP 在 AVR 后均有所改善，但在 AS-T2D 患者中未观察到这些评估的改善。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在严重 AS 患者中，患有 T2D 的患者在 AVR 后表现出心肌 PCr/ATP、血管舒张应激 MBF 和心脏收缩功能的持续异常；AVR 有效地使未接受 AVR 的患者的心肌 PCr/ATP、血管舒张应激 MBF 和心脏收缩功能正常化。 T2D。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37746744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37746744</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063444>10.1161 / CIRCULATIONAHA.122.063444</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37746744</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>尼古拉斯·杰克斯</dc:creator><dc:creator>约翰·P·格林伍德</dc:creator><dc:creator>理查德·库本</dc:creator><dc:creator>奥利弗·J·莱德</dc:creator><dc:creator>阿姆里特·乔杜里</dc:creator><dc:creator>沙曼·蒂鲁纳乌卡拉苏</dc:creator><dc:creator>辛杜拉·科塔</dc:creator><dc:creator>玛丽娜·贾努迪</dc:creator><dc:creator>安娜·麦格莱恩</dc:creator><dc:creator>阿曼达·麦克坎内尔</dc:creator><dc:creator>马塞拉·康宁-罗兰</dc:creator><dc:creator>萨姆·斯特劳</dc:creator><dc:creator>亨利·普罗克特</dc:creator><dc:creator>索蒂里斯·帕帕斯皮罗斯</dc:creator><dc:creator>贝特西·埃文斯</dc:creator><dc:creator>卡利亚纳·贾文古拉</dc:creator><dc:creator>安东内拉·费拉拉</dc:creator><dc:creator>瓦利德·埃尔马迪</dc:creator><dc:creator>潘卡吉·考尔</dc:creator><dc:creator>雪慧</dc:creator><dc:creator>彼得·斯沃博达</dc:creator><dc:creator>彼得·凯尔曼</dc:creator><dc:creator>拉迪斯拉夫·瓦尔科维奇</dc:creator><dc:creator>李·罗伯茨</dc:creator><dc:creator>大卫·比奇</dc:creator><dc:creator>马克·T·科尔尼</dc:creator><dc:creator>斯文·普莱因</dc:creator><dc:creator>马克·R·德韦克</dc:creator><dc:creator>埃莱姆·莱弗特</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>2 型糖尿病与重度主动脉瓣狭窄患者主动脉瓣置换术前后心肌结构、收缩功能、能量学和血流变化之间的关系</dc:title><dc:identifier>下午:37746744</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063444</dc:identifier></item><item><title>免疫检查点抑制剂心肌炎中致病性心脏巨噬细胞的扩增</title><link/>https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>结论：这些数据表明 ICI 心肌炎与 IFN-γ 诱导的炎症巨噬细胞特定群体的扩张有关，并表明 IFN-γ 阻断可能被视为这种破坏性病症的治疗选择。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 25 日。doi：10.1161/CIRCULATIONAHA.122.062551。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：免疫检查点抑制剂 (ICIs)、针对 PD-1（程序性细胞死亡蛋白 1）/PD-L1（程序性死亡配体 1）或 CTLA4（细胞毒性 T 淋巴细胞相关蛋白 4）的抗体已经彻底改变了癌症治疗，但与包括心肌炎在内的破坏性免疫相关不良事件相关。ICI 心肌炎的主要危险因素是联合使用 PD-1 和 CTLA4 抑制。ICI 心肌炎通常是暴发性的，病理学特征为 T 淋巴细胞和巨噬细胞的心肌浸润。人们对 T 细胞在 ICI 心肌炎中的作用了解甚少，但对浸润巨噬细胞的身份、转录多样性和功能了解甚少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用已建立的小鼠 ICI 心肌炎模型（ <i>Ctla4</i> <sup><i>+/-</i></sup> <i>Pdcd1</i> <sup><i>-/-</i></sup>小鼠），通过单细胞 RNA 测序、免疫染色、流式细胞术、原位 RNA 杂交、分子成像和抗体来探索心脏免疫景观中和研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们在该模型中观察到 CCR2（CC 趋化因子受体 2 型） <sup>+</sup>单核细胞衍生的巨噬细胞和 CD8 <sup>+</sup> T 细胞显着增加。巨噬细胞区室是异质的，并且在高度表达<i>Cxcl9</i> （趋化因子）的炎症 CCR2 <sup>+</sup>亚群中显示出显着富集。 [CXC 基序] 配体 9)、 <i>Cxcl10</i> （趋化因子 [CXC 基序] 配体 10）、 <i>Gbp2b</i> （干扰素诱导的鸟苷酸结合蛋白 2b）和源自 CCR2 <sup>+</sup>单核细胞的<i>Fcgr4</i> （Fc 受体，IgG，低亲和力 IV）。重要的是，表达<i>CXCL9</i> 、 <i>CXCL10</i>和 CD16α（小鼠 FcgR4 的人类同源物）的类似巨噬细胞群在 ICI 心肌炎患者中得到扩展。细胞间通讯的计算机预测表明 T 细胞与<i>Cxcl9</i> <sup><i>+</i></sup> <i>Cxcl10</i> <sup><i>+</i></sup>巨噬细胞之间存在相互作用通过 IFN-γ（干扰素 γ）和 CXCR3（CXC 趋化因子受体 3）信号通路。消耗 CD8 <sup>+</sup> T 细胞、巨噬细胞和阻断 IFN-γ 信号传导可减弱心脏中<i>Cxcl9</i> <sup><i>+</i></sup> <i>Cxcl10</i> <sup><i>+</i></sup>巨噬细胞的扩张并减轻心肌炎，表明这种相互作用对于疾病发病机制是必要的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些数据表明 ICI 心肌炎与 IFN-γ 诱导的炎症巨噬细胞特定群体的扩张有关，并表明 IFN-γ 阻断可能被视为这种破坏性病症的治疗选择。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37746718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37746718</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062551>10.1161 / CIRCULATIONAHA.122.062551</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37746718</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>盘马</dc:creator><dc:creator>刘静</dc:creator><dc:creator>秦娟</dc:creator><dc:creator>赖露露</dc:creator><dc:creator>圭成许</dc:creator><dc:creator>汉娜·卢曼</dc:creator><dc:creator>黛博拉·苏丹</dc:creator><dc:creator>安德里亚·布雷德迈耶</dc:creator><dc:creator>吉蒂卡·巴贾帕</dc:creator><dc:creator>冯国帅</dc:creator><dc:creator>赫苏斯·希门尼斯</dc:creator><dc:creator>何瑞军</dc:creator><dc:creator>安塔尼沙公园</dc:creator><dc:creator>朱德·阿姆鲁特</dc:creator><dc:creator>安娜·维拉纽瓦</dc:creator><dc:creator>刘永健</dc:creator><dc:creator>林杰玉</dc:creator><dc:creator>马蒂亚斯·麦克</dc:creator><dc:creator>考希克·阿曼切拉</dc:creator><dc:creator>贾维德·莫斯莱希</dc:creator><dc:creator>科里·J·拉文</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>免疫检查点抑制剂心肌炎中致病性心脏巨噬细胞的扩增</dc:title><dc:identifier>下午:37746718</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.062551</dc:identifier></item><item><title> NSTEMI PCI 期间比伐卢定与肝素：大型随机试验的个体患者数据荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>结论：在接受 PCI 的非 ST 段抬高型心肌梗死患者中，使用比伐卢定和肝素进行抗凝治疗并没有导致死亡率或缺血事件（包括支架内血栓形成和再梗塞）发生率显着不同。与肝素相比，比伐卢定减少了严重出血的发生率来自访问站点和非访问站点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 25 日。doi：10.1161/CIRCULATIONAHA.123.063946。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：比伐卢定与肝素抗凝治疗接受经皮冠状动脉介入治疗 (PCI) 的非 ST 段抬高型心肌梗死患者的益处：风险状况尚不确定。研究水平的荟萃分析缺乏粒度，无法提供结论性答案。我们试图比较比伐卢定和肝素在接受 PCI 的非 ST 段抬高型心肌梗死患者中的结局。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对所有 5 项试验中的非 ST 段抬高型心肌梗死患者进行了个体患者数据荟萃分析，将 ≥1000 名接受 PCI 的任何心肌梗死患者随机分配至比伐卢定与肝素组（MATRIX、VALIDATE-SWEDEHEART、ISAR） -REACT 4、ACUITY [急性导管插入和紧急干预分诊策略] 和 BRIGHT）。主要有效性和安全性终点是 30 天全因死亡率和严重出血。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 12 155 名患者被随机分配：6040 名患者接受比伐卢定治疗（PCI 后比伐卢定输注为 52.3%），6115 名患者接受肝素治疗（计划使用糖蛋白 IIb/IIIa 抑制剂为 53.2%）。30 天死亡率并不显着。比伐卢定和肝素之间存在差异（1.2% 与 1.1%；调整后优势比，1.24 [95% CI, 0.86-1.79]； <i>P</i> = 0.25）。心脏死亡率、再梗塞和支架内血栓形成率也没有显着差异。比伐卢定严重降低与肝素相比，出血（穿刺部位相关和非穿刺部位相关）（3.3% vs 5.5%；调整后优势比，0.59；95% CI，0.48-0.72； <i>P</i> &lt;0.0001）。无论使用何种方法，结果都是一致的PCI 后比伐卢定输注或常规糖蛋白 IIb/IIIa 抑制剂与肝素一起使用以及 1 年随访期间的情况。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在接受 PCI 的非 ST 段抬高型心肌梗死患者中，使用比伐卢定和肝素进行抗凝治疗并没有导致死亡率或缺血事件（包括支架内血栓形成和再梗塞）发生率显着不同。与肝素相比，比伐卢定减少了严重出血的发生率来自访问站点和非访问站点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37746717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37746717</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063946>10.1161 / CIRCULATIONAHA.123.063946</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37746717</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>贝努德·比克德里</dc:creator><dc:creator>大卫·埃尔林格</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>阿德南·卡斯特拉蒂</dc:creator><dc:creator>韩雅玲</dc:creator><dc:creator>菲利普·加布里埃尔·施泰格</dc:creator><dc:creator>罗德 H 马厩</dc:creator><dc:creator>罗克珊娜·迈赫兰</dc:creator><dc:creator>斯蒂芬·K·詹姆斯</dc:creator><dc:creator>恩里科·弗里戈利</dc:creator><dc:creator>帕特里克·戈德斯坦</dc:creator><dc:creator>李毅</dc:creator><dc:creator>阿迪尔·沙赫扎德</dc:creator><dc:creator>斯蒂芬妮·舒普克</dc:creator><dc:creator>加扎拉·迈赫迪普尔</dc:creator><dc:creator>陈施穆尔</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>亚伦·克劳利</dc:creator><dc:creator>周志鹏</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>NSTEMI PCI 期间比伐卢定与肝素：大型随机试验的个体患者数据荟萃分析</dc:title><dc:identifier>下午：37746717</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.063946</dc:identifier></item><item><title>高敏心肌肌钙蛋白 I 引导联合血管紧张素受体阻断和 β 受体阻滞剂治疗预防蒽环类药物心脏毒性的多中心、前瞻性、随机对照试验：Cardiac CARE 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37746692/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>结论：坎地沙坦和卡维地洛联合治疗对于接受以蒽环类药物为基础的化疗且治疗中心肌肌钙蛋白 I 浓度高风险的患者没有明显的心脏保护作用。低风险非随机患者的左心室射血分数也有类似的下降，这引起了人们对其效用的质疑。常规心肌肌钙蛋白监测。此外，左心室射血分数的适度下降表明其价值和临床... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 25 日。doi：10.1161/CIRCULATIONAHA.123.064274。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：蒽环类药物引起的心脏毒性的发生率各不相同，左心室功能障碍的发生先于心肌肌钙蛋白浓度的升高。β-肾上腺素能受体阻滞剂和肾素-血管紧张素系统抑制剂治疗在未经选择的接受治疗的患者中与适度的心脏保护作用相关。蒽环类化疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在一项多中心、前瞻性、随机、开放、盲法终点试验中，接受蒽环类化疗的乳腺癌和非霍奇金淋巴瘤患者在治疗前和治疗后 6 个月接受了系列高敏心肌肌钙蛋白检测和心脏磁共振成像蒽环类药物治疗。心脏毒性高风险患者（化疗期间心肌肌钙蛋白 I 浓度位于上三分位数）被随机分配至标准治疗加心脏保护（卡维地洛和坎地沙坦联合治疗）或单独标准治疗。主要结局是左心室射血的调整变化在心肌肌钙蛋白 I 浓度处于较低 2 个三分位的低风险非随机患者中，我们重新发现左心室射血分数 6 个月内没有变化，并测试了 ±2% 的等效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：2017 年 10 月至 2021 年 6 月期间，招募了 175 名患者（平均年龄 53 岁；87% 为女性；71% 患有乳腺癌）。随机接受心脏保护 (n=29) 或标准护理 (n=28) 的患者已离开基线时心室射血分数分别为 69.4±7.4% 和 69.1±6.1%，化疗完成后 6 个月分别为 65.7±6.6% 和 64.9±5.9%。在调整年龄、治疗前左心室射血分数和计划蒽环类药物剂量后，心脏保护组和标准护理组之间 6 个月左心室射血分数的估计平均差异为 -0.37%（95% CI，-3.59% 至 2.85%； <i>P</i> =0.82）。在低风险非随机患者中，基线和 6一个月左心室射血分数分别为 69.3±5.7% 和 66.4±6.3%：估计平均差为 2.87%（95% CI，1.63%-4.10%； <i>P</i> =0.92，不相等）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：坎地沙坦和卡维地洛联合治疗对于接受以蒽环类药物为基础的化疗且治疗中心肌肌钙蛋白 I 浓度高风险的患者没有明显的心脏保护作用。低风险非随机患者的左心室射血分数也有类似的下降，这引起了人们对其效用的质疑。此外，左心室射血分数的适度下降表明，需要更好地确定接受大剂量蒽环类药物的患者早期心脏保护治疗的价值和临床影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https://doi.org/10.1186/ISRCTN24439460；唯一标识符，ISRCTN24439460。URL：https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000896-99；唯一标识符： EudraCT 2017-000896-99。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37746692/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37746692</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064274>10.1161 / CIRCULATIONAHA.123.064274</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37746692</guid><pubDate> Mon, 25 Sep 2023 06:00:00 -0400</pubDate><dc:creator>彼得·亨里克森</dc:creator><dc:creator>彼得·霍尔</dc:creator><dc:creator>伊恩·麦克弗森</dc:creator><dc:creator>施鲁蒂·乔希</dc:creator><dc:creator>特丽莎·辛格</dc:creator><dc:creator>莫拉格·麦克莱恩</dc:creator><dc:creator>史蒂夫·刘易斯</dc:creator><dc:creator>阿雷利·罗德里格斯</dc:creator><dc:creator>亚历克斯·弗莱彻</dc:creator><dc:creator>拉塞尔·埃弗雷特</dc:creator><dc:creator>哈丽特·斯塔弗特</dc:creator><dc:creator>安格斯·布鲁姆</dc:creator><dc:creator>路易斯·埃迪</dc:creator><dc:creator>洛林·普里姆罗斯</dc:creator><dc:creator>希瑟·麦克维卡斯</dc:creator><dc:creator>帕姆·麦凯</dc:creator><dc:creator>安娜贝尔·博利</dc:creator><dc:creator>克莱尔·朗特里</dc:creator><dc:creator>西蒙·洛德</dc:creator><dc:creator>格雷厄姆·柯林斯</dc:creator><dc:creator>约翰·雷德福</dc:creator><dc:creator>艾米孔雀鱼</dc:creator><dc:creator>米歇尔·C·威廉姆斯</dc:creator><dc:creator>艾伦·贾普</dc:creator><dc:creator>约翰·R·佩恩</dc:creator><dc:creator>大卫·E·纽比</dc:creator><dc:creator>尼克·L·米尔斯</dc:creator><dc:creator>奥尔加·奥科诺米杜</dc:creator><dc:creator>尼尼安·朗</dc:creator><dc:date>2023-09-25</dc:date><dc:source>循环</dc:source><dc:title>高敏心肌肌钙蛋白 I 引导联合血管紧张素受体阻断和 β 受体阻滞剂治疗预防蒽环类药物心脏毒性的多中心、前瞻性、随机对照试验：Cardiac CARE 试验</dc:title><dc:identifier>下午:37746692</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064274</dc:identifier></item><item><title>更正：管理心血管疾病的心理健康和情绪方面：患者休息室的观点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37742083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 22:ehad589.doi: 10.1093/eurheartj/ehad589. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37742083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37742083</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad589>10.1093/eurheartj/ehad589</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37742083</guid><pubDate> Sun, 24 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-24</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>更正：管理心血管疾病的心理健康和情绪方面：患者休息室的观点</dc:title><dc:identifier>下午：37742083</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad589</dc:identifier></item><item><title>淀粉体沉降使 LAZY 重新极化以实现植物的重力感应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37741279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>重力控制植物的定向生长，一个多世纪前提出的经典淀粉平衡石假说假设特殊细胞中的淀粉体沉积启动重力感应，但分子机制仍未表征。LAZY 蛋白被称为向地性的关键调节因子，并且懒惰突变体表现出显着的向重力缺陷。在这里，我们报告说，通过重新定向来刺激重力会触发丝裂原激活蛋白激酶 (MAPK)... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 20 日：S0092-8674(23)01035-8. doi: 10.1016/j.cell.2023.09.014. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重力控制植物的定向生长，一个多世纪前提出的经典淀粉平衡石假说假设特殊细胞中的淀粉体沉积启动重力感应，但分子机制仍未表征。LAZY 蛋白被称为向地性的关键调节因子，并且懒惰突变体表现出显着的向重力缺陷。在这里，我们报告说，通过重新定向的重力刺激会触发丝裂原激活蛋白激酶（MAPK）信号介导的拟南芥LAZY蛋白在根小柱细胞中基底极化的磷酸化。LAZY的磷酸化增加了其与多个易位子的相互作用造粉体表面叶绿体 (TOC) 蛋白的外膜，促进 LAZY 蛋白在造粉体上的富集。造粉体沉降随后引导 LAZY 重新定位到小柱细胞质膜的新下侧，其中 LAZY 诱导不对称的生长素分布，并且根差异生长. 总之，这项研究为淀粉平衡石假说提供了分子解释：细胞器运动触发分子极性形成。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37741279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37741279</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.014>10.1016/j.cell.2023.09.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37741279</guid><pubDate> Sat, 23 Sep 2023 06:00:00 -0400</pubDate><dc:creator>陈家跃</dc:creator><dc:creator>于仁波</dc:creator><dc:creator>李娜</dc:creator><dc:creator>邓兆国</dc:creator><dc:creator>张欣欣</dc:creator><dc:creator>赵雅然</dc:creator><dc:creator>成府区</dc:creator><dc:creator>袁艳芳</dc:creator><dc:creator>潘哲贤</dc:creator><dc:creator>周阳阳</dc:creator><dc:creator>李昆仑</dc:creator><dc:creator>王家俊</dc:creator><dc:creator>陈志仁</dc:creator><dc:creator>王晓仪</dc:creator><dc:creator>王晓莲</dc:creator><dc:creator>何树楠</dc:creator><dc:creator>董娟</dc:creator><dc:creator>邓兴旺</dc:creator><dc:creator>陈浩东</dc:creator><dc:date>2023-09-23</dc:date><dc:source>细胞</dc:source><dc:title>淀粉体沉降使 LAZY 重新极化以实现植物的重力感应</dc:title><dc:identifier>下午：37741279</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.014</dc:identifier></item><item><title> Bentall 手术后出现“瓣周漏”，但不是瓣周漏</title><link/>https://pubmed.ncbi.nlm.nih.gov/37740945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 23:ehad607.doi: 10.1093/eurheartj/ehad607. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37740945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37740945</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad607>10.1093/eurheartj/ehad607</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37740945</guid><pubDate> Sat, 23 Sep 2023 06:00:00 -0400</pubDate><dc:creator>穆罕默德·伊德里斯</dc:creator><dc:creator>阿伦·库马尔</dc:creator><dc:creator>巴什韦拉尤丹</dc:creator><dc:date>2023-09-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Bentall 手术后出现“瓣周漏”，但不是瓣周漏</dc:title><dc:identifier>下午：37740945</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad607</dc:identifier></item><item><title>颈椎病诱发的长QT综合征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37740436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 22:ehad608.doi: 10.1093/eurheartj/ehad608. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37740436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37740436</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad608>10.1093/eurheartj/ehad608</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37740436</guid><pubDate> Sat, 23 Sep 2023 06:00:00 -0400</pubDate><dc:creator>恩力</dc:creator><dc:creator>严超武</dc:creator><dc:creator>杨晓宇</dc:creator><dc:date>2023-09-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>颈椎病诱发的长QT综合征</dc:title><dc:identifier>下午：37740436</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad608</dc:identifier></item><item><title>心包切开术治疗射血分数保留的心力衰竭：第一项临床研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37740430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 22:ehad620.doi: 10.1093/eurheartj/ehad620. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37740430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37740430</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad620>10.1093/eurheartj/ehad620</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37740430</guid><pubDate> Sat, 23 Sep 2023 06:00:00 -0400</pubDate><dc:creator>巴里·博洛格</dc:creator><dc:creator>哈泽尔诉沙夫</dc:creator><dc:creator>塞缪尔·J·阿瑟瓦瑟姆</dc:creator><dc:creator>凯特琳·E·科普</dc:creator><dc:creator>威廉·J·莫尔曼</dc:creator><dc:creator>菲利普·G·罗斯</dc:creator><dc:date>2023-09-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心包切开术治疗射血分数保留的心力衰竭：第一项临床研究</dc:title><dc:identifier>下午：37740430</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad620</dc:identifier></item><item><title> SARS-CoV-2 变体进化出收敛策略来重塑宿主反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37738970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description> SARS-CoV-2 关注变体 (VOC) 在 COVID-19 大流行期间出现。在这里，我们使用无偏系统方法来研究驱动 VOC 进化的宿主选择力。我们发现 VOC 进化出收敛策略，通过调节来重塑宿主病毒 RNA 和蛋白质水平，改变病毒和宿主蛋白质磷酸化，并重新连接病毒-宿主蛋白质-蛋白质相互作用。综合计算分析表明，尽管 Alpha、Beta、Gamma 和 Delta 最终... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 19 日：S0092-8674(23)00915-7. doi: 10.1016/j.cell.2023.08.026. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-CoV-2 关注变体 (VOC) 在 COVID-19 大流行期间出现。在这里，我们使用无偏系统方法来研究驱动 VOC 进化的宿主选择力。我们发现 VOC 进化出收敛策略，通过调节来重塑宿主病毒 RNA 和蛋白质水平，改变病毒和宿主蛋白质磷酸化，并重新连接病毒-宿主蛋白质-蛋白质相互作用。综合计算分析表明，尽管 Alpha、Beta、Gamma 和 Delta 最终汇聚到抑制干扰素刺激基因 (ISG)，但 Omicron BA.1 没有。ISG 抑制与病毒先天免疫拮抗蛋白的表达相关，包括 Orf6、N 和 Orf9b，我们将其映射到特定突变。后来的 Omicron 亚变体 BA.4 和 BA.5 比它更有效地抑制先天免疫。早期亚变体 BA.1，与 Orf6 水平相关，尽管在 BA.4 中由于破坏 Orf6 与核孔相互作用的突变而被抑制。我们的研究结果表明，SARS-CoV-2 趋同进化克服了人类适应性和先天免疫障碍，奠定了基础为应对未来流行病奠定基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37738970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37738970</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.026>10.1016/j.cell.2023.08.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37738970</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator>迈赫迪·布哈杜</dc:creator><dc:creator>安-凯瑟琳·罗伊施尔</dc:creator><dc:creator>本杰明·波拉科</dc:creator><dc:creator>露西·G·索恩</dc:creator><dc:creator>马尼沙·R·乌马迪</dc:creator><dc:creator>叶成金</dc:creator><dc:creator>罗梅尔·罗萨莱斯</dc:creator><dc:creator>阿德里安·佩林</dc:creator><dc:creator>乔蒂·巴特拉</dc:creator><dc:creator>格温多林·M·张</dc:creator><dc:creator>徐杰伟</dc:creator><dc:creator>杰克·莫恩</dc:creator><dc:creator>艾丽西亚·L·理查兹</dc:creator><dc:creator>袁州</dc:creator><dc:creator>巴维亚·哈贾伊</dc:creator><dc:creator>艾丽卡·史蒂文森</dc:creator><dc:creator>阿吉达·罗伊克</dc:creator><dc:creator>罗伯塔·拉加齐尼</dc:creator><dc:creator>马修·VX·惠兰</dc:creator><dc:creator>威廉·弗农</dc:creator><dc:creator>朱迪塔·德·洛伦佐</dc:creator><dc:creator>凡妮莎·考顿</dc:creator><dc:creator>阿卜杜拉·赛义德</dc:creator><dc:creator>艾莉森·西林</dc:creator><dc:creator>诺亚·多伊奇</dc:creator><dc:creator>丹尼尔·皮拉克</dc:creator><dc:creator>朱莉娅·道吉尔</dc:creator><dc:creator>德扬·梅斯纳</dc:creator><dc:creator>简·L·特纳</dc:creator><dc:creator>布莱恩娜·L·麦戈文</dc:creator><dc:creator>M路易斯·罗德里格斯</dc:creator><dc:creator>罗西奥·雷瓦-雷博洛</dc:creator><dc:creator>阿利斯泰尔·邓纳姆</dc:creator><dc:creator>钟晓芳</dc:creator><dc:creator>曼农·埃克哈特</dc:creator><dc:creator>安德里亚·福萨蒂</dc:creator><dc:creator>尼古拉斯·F·利奥塔</dc:creator><dc:creator>托马斯·凯勒</dc:creator><dc:creator>阿纳斯塔西娅·丘皮克</dc:creator><dc:creator>玛格达莱娜·鲁特科斯卡</dc:creator><dc:creator>伊格纳西奥·梅纳</dc:creator><dc:creator>萨达夫·阿斯拉姆</dc:creator><dc:creator>艾莉莎·霍弗特</dc:creator><dc:creator>海伦·福萨德</dc:creator><dc:creator>查尔斯·奥钦·奥尔瓦尔</dc:creator><dc:creator>黄伟庆</dc:creator><dc:creator>托马斯·兹瓦卡</dc:creator><dc:creator>约翰·范</dc:creator><dc:creator>莫莉·莱昂斯</dc:creator><dc:creator>劳拉·多诺霍</dc:creator><dc:creator>阿莉莎·格里芬</dc:creator><dc:creator>丽贝卡·纽金特</dc:creator><dc:creator>凯文·霍尔登</dc:creator><dc:creator>罗伯特·迪恩斯</dc:creator><dc:creator>巴勃罗·阿维莱斯</dc:creator><dc:creator>何塞·洛佩斯·马丁</dc:creator><dc:creator>何塞·M·希梅诺</dc:creator><dc:creator>克尔斯滕·奥伯尼尔</dc:creator><dc:creator>杰奎琳·M·法比尤斯</dc:creator><dc:creator>玛格丽特·苏切雷</dc:creator><dc:creator>露丝·胡滕海恩</dc:creator><dc:creator>欧文·荣格莱斯</dc:creator><dc:creator>马诺利斯·凯利斯</dc:creator><dc:creator>伊格纳西娅·埃切维里亚</dc:creator><dc:creator>克里门特·维尔巴</dc:creator><dc:creator>保拉·邦凡蒂</dc:creator><dc:creator>佩德罗·贝尔特劳</dc:creator><dc:creator>罗德·夏兰</dc:creator><dc:creator>詹妮弗·杜德纳</dc:creator><dc:creator>路易斯·马丁内斯-索布里多</dc:creator><dc:creator>阿文德·H·帕特尔</dc:creator><dc:creator>马西莫·帕尔马里尼</dc:creator><dc:creator>丽莎·米奥林</dc:creator><dc:creator>克里斯·怀特</dc:creator><dc:creator>丹妮尔·L·斯瓦尼</dc:creator><dc:creator>阿道夫·加西亚·萨斯特雷</dc:creator><dc:creator>克莱尔乔利</dc:creator><dc:creator>洛雷娜·祖利亚尼-阿尔瓦雷斯</dc:creator><dc:creator>格雷格·J·塔尔斯</dc:creator><dc:creator>内万·J·克罗根</dc:creator><dc:date>2023-09-22</dc:date><dc:source>细胞</dc:source><dc:title>SARS-CoV-2 变体进化出收敛策略来重塑宿主反应</dc:title><dc:identifier>下午:37738970</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.026</dc:identifier></item><item><title>我们能否显着提高对复发性冠状动脉疾病事件的预测？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 9 月 21 日；44(36):3466-3468.doi: 10.1093/eurheartj/ehad464。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37738645</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad464>10.1093/eurheartj/ehad464</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37738645</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator>威廉·温特劳布</dc:creator><dc:creator>威廉·博登</dc:creator><dc:date>2023-09-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>我们能否显着提高对复发性冠状动脉疾病事件的预测？</dc:title><dc:identifier>下午：37738645</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad464</dc:identifier></item><item><title>预测的挑战和机遇：关注缺血性心脏病和心房颤动</title><link/>https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 9 月 21 日；44(36):3391-3394.doi: 10.1093/eurheartj/ehad614。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37738644</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad614>10.1093/eurheartj/ehad614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37738644</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-09-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>预测的挑战和机遇：关注缺血性心脏病和心房颤动</dc:title><dc:identifier>下午:37738644</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad614</dc:identifier></item><item><title>更正：2023 ESC 心内膜炎管理指南：由欧洲心脏病学会 (ESC) 心内膜炎管理工作组制定，并得到欧洲心胸外科协会 (EACTS) 和欧洲核协会认可医学（EANM）</title><link/> https://pubmed.ncbi.nlm.nih.gov/37738322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 20:ehad625.doi: 10.1093/eurheartj/ehad625. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37738322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37738322</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad625>10.1093/eurheartj/ehad625</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37738322</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>更正：2023 ESC 心内膜炎管理指南：由欧洲心脏病学会 (ESC) 心内膜炎管理工作组制定，并得到欧洲心胸外科协会 (EACTS) 和欧洲核协会认可医学（EANM）</dc:title><dc:identifier>下午:37738322</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad625</dc:identifier></item><item><title>出生体重影响心脏结构、功能和疾病风险：因果关系的证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37738114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230925160831&amp;v=2.17.9.post6+86293ac<description>结论：这项研究的结果支持低出生体重与心血管疾病的因果关系，即使考虑了宫内环境的影响。这表明低出生体重的个体可能受益于有针对性的早期心血管疾病预防策略，独立的这是否与妊娠期间不利的宫内环境有关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 20:ehad631.doi: 10.1093/eurheartj/ehad631. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：低出生体重是一种常见的妊娠并发症，与晚年罹患心脏代谢疾病的较高风险相关。之前探索此问题的孟德尔随机化 (MR) 研究并未区分直接影响出生体重的变异的机制贡献通过胎儿基因组（直接胎儿影响），与通过引起不利的子宫内环境间接影响出生体重的变异（间接母体影响）。在这项研究中，MR 用于评估独立于子宫内影响的出生体重是否与心血管疾病风险以及不良心脏结构和功能的测量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从全基因组关联研究总体出生体重的汇总统计数据中提取不相关（r2 &lt; .001）、全基因组显着性（P &lt; 5 × 10-8）单核苷酸多态性，并且仅在分离直接胎儿影响后进行。方差加权 MR 用于分析心房颤动、冠状动脉疾病、心力衰竭、缺血性中风以及 16 项心脏结构和功能测量的结果。通过 Benjamini-Hochberg 校正进行多重比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：较低的遗传预测出生体重（仅隔离对胎儿的直接影响）与冠状动脉疾病风险增加（比值比 1.21，95% 置信区间 1.06-1.37；P = 0.031）、较小的心室容积和较低的冠状动脉疾病风险相关。每搏输出量，但收缩力较高。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The results of this study support a causal role of low birth weight in cardiovascular disease, even after accounting for the influence of the intrauterine environment. This suggests that individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37738114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37738114</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad631>10.1093/eurheartj/ehad631</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37738114</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Maddalena Ardissino</dc:creator><dc:creator> Alec P Morley</dc:creator><dc:creator> Eric AW Slob</dc:creator><dc:creator> Art Schuermans</dc:creator><dc:creator> Bilal Rayes</dc:creator><dc:creator> Zahra Raisi-Estabragh</dc:creator><dc:creator> Antonio de Marvao</dc:creator><dc:creator> Stephen Burgess</dc:creator><dc:creator> Tormod Rogne</dc:creator><dc:creator> Michael C Honigberg</dc:creator><dc:creator> Fu Siong Ng</dc:creator><dc:date> 2023-09-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Birth weight influences cardiac structure, function, and disease risk: evidence of a causal association</dc:title><dc:identifier> pmid:37738114</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad631</dc:identifier></item><item><title> PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Patients with AF exhibit increased levels of PPP1R12C protein compared with controls. PPP1R12C overexpression in mice increases PP1c targeting to MLC2a and causes MLC2a dephosphorylation, which reduces atrial contractility and increases AF inducibility. These findings suggest that PP1 regulation of sarcomere function at MLC2a is a key determinant of atrial contractility in AF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 22. doi: 10.1161/CIRCRESAHA.123.322516. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Atrial fibrillation (AF)-the most common sustained cardiac arrhythmia-increases thromboembolic stroke risk 5-fold. Although atrial hypocontractility contributes to stroke risk in AF, the molecular mechanisms reducing myofilament contractile function remain unknown. We tested the hypothesis that increased expression of PPP1R12C (protein phosphatase 1 regulatory subunit 12C)-the PP1 (protein phosphatase 1) regulatory subunit targeting MLC2a (atrial myosin light chain 2)-causes hypophosphorylation of MLC2a and results in atrial hypocontractility. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Right atrial appendage tissues were isolated from human patients with AF versus sinus rhythm controls. Western blots, coimmunoprecipitation, and phosphorylation studies were performed to examine how the PP1c (PP1 catalytic subunit)-PPP1R12C interaction causes MLC2a dephosphorylation. In vitro studies of pharmacological MRCK (myotonic dystrophy kinase-related Cdc42-binding kinase) inhibitor (BDP5290) in atrial HL-1 cells were performed to evaluate PP1 holoenzyme activity on MLC2a. Cardiac-specific lentiviral PPP1R12C overexpression was performed in mice to evaluate atrial remodeling with atrial cell shortening assays, echocardiography, and AF inducibility with electrophysiology studies. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In human patients with AF, PPP1R12C expression was increased 2-fold versus sinus rhythm controls ( <i>P</i> =2.0×10 <sup>-</sup> <sup>2</sup> ; n=12 and 12 in each group) with >;40% reduction in MLC2a phosphorylation ( <i>P</i> =1.4×10 <sup>-</sup> <sup>6</sup> ; n=12 and 12 in each group). PPP1R12C-PP1c binding and PPP1R12C-MLC2a binding were significantly increased in AF ( <i>P</i> =2.9×10 <sup>-2</sup> and 6.7×10 <sup>-3</sup> , respectively; n=8 and 8 in each group). In vitro studies utilizing drug BDP5290, which inhibits T560-PPP1R12C phosphorylation, demonstrated increased PPP1R12C binding with both PP1c and MLC2a and dephosphorylation of MLC2a. Mice treated with lentiviral PPP1R12C vector demonstrated a 150% increase in left atrial size versus controls ( <i>P</i> =5.0×10 <sup>-</sup> <sup>6</sup> ; n=12, 8, and 12), with reduced atrial strain and atrial ejection fraction. Pacing-induced AF in mice treated with lentiviral PPP1R12C vector was significantly higher than in controls ( <i>P</i> =1.8×10 <sup>-2</sup> and 4.1×10 <sup>-2</sup> , respectively; n=6, 6, and 5). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Patients with AF exhibit increased levels of PPP1R12C protein compared with controls. PPP1R12C overexpression in mice increases PP1c targeting to MLC2a and causes MLC2a dephosphorylation, which reduces atrial contractility and increases AF inducibility. These findings suggest that PP1 regulation of sarcomere function at MLC2a is a key determinant of atrial contractility in AF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37737016</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322516>10.1161/CIRCRESAHA.123.322516</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37737016</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Srikanth Perike</dc:creator><dc:creator> Francisco J Gonzalez-Gonzalez</dc:creator><dc:creator> Issam Abu-Taha</dc:creator><dc:creator> Frederick W Damen</dc:creator><dc:creator> Laurin M Hanft</dc:creator><dc:creator> Ken S Lizama</dc:creator><dc:creator> Anahita Aboonabi</dc:creator><dc:creator> Andrielle E Capote</dc:creator><dc:creator> Yuriana Aguilar-Sanchez</dc:creator><dc:creator> Benjamin Levin</dc:creator><dc:creator> Zhenbo Han</dc:creator><dc:creator> Arvind Sridhar</dc:creator><dc:creator> Jacob Grand</dc:creator><dc:creator> Jody Martin</dc:creator><dc:creator> Joseph G Akar</dc:creator><dc:creator> Chad M Warren</dc:creator><dc:creator> R John Solaro</dc:creator><dc:creator> Sang-Ging Ong</dc:creator><dc:creator> Dawood Darbar</dc:creator><dc:creator> Kerry S McDonald</dc:creator><dc:creator> Craig J Goergen</dc:creator><dc:creator> Beata M Wolska</dc:creator><dc:creator> Dobromir Dobrev</dc:creator><dc:creator> Xander HT Wehrens</dc:creator><dc:creator> Mark D McCauley</dc:creator><dc:date> 2023-09-22</dc:date><dc:source> Circulation research</dc:source><dc:title> PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation</dc:title><dc:identifier> pmid:37737016</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322516</dc:identifier></item><item><title> Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International</title><link/> https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> In 2017, the World Health Organization (WHO) and Resolve to Save Lives partnered with country governments and other stakeholders to design, test, and scale up the WHO HEARTS hypertension services package in 32 low- and middle-income countries. Facility-based HEARTS performance indicators included number of patients enrolled, number treated and with blood pressure controlled, number who missed a scheduled follow-up visit, and number lost to follow-up. By 2022, HEARTS hypertension control programs... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 19:S0735-1097(23)06633-0. doi: 10.1016/j.jacc.2023.08.043. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> In 2017, the World Health Organization (WHO) and Resolve to Save Lives partnered with country governments and other stakeholders to design, test, and scale up the WHO HEARTS hypertension services package in 32 low- and middle-income countries. Facility-based HEARTS performance indicators included number of patients enrolled, number treated and with blood pressure controlled, number who missed a scheduled follow-up visit, and number lost to follow-up. By 2022, HEARTS hypertension control programs treated 12.2 million patients in 165,000 primary care facilities. Hypertension control was 38% (median 48%; range 5%-86%). In 4 HEARTS countries using the same digital health information system, facility-based control improved from 18% at baseline to 46% in 48 months. At the population level, median estimated population-based hypertension control was 11.0% of all hypertension patients (range 2.0%-34.7%). The Global Hearts experience of implementing WHO HEARTS demonstrates the feasibility of controlling hypertension in low- and middle-income country primary care settings.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37734459</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.043>10.1016/j.jacc.2023.08.043</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37734459</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Andrew E Moran</dc:creator><dc:creator> Reena Gupta</dc:creator><dc:creator> Global Hearts Initiative Collaborators</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International</dc:title><dc:identifier> pmid:37734459</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.043</dc:identifier></item><item><title> Mpox infection protects against re-challenge in rhesus macaques</title><link/> https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes and observed robust antibody and T cell responses following all three routes of infection. Numerous skin lesions and high plasma viral loads were observed following intravenous and intradermal infection. Skin lesions peaked on day 10 and resolved by day 28 following infection. On day 28, we re-challenged all... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 13:S0092-8674(23)00911-X. doi: 10.1016/j.cell.2023.08.023. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes and observed robust antibody and T cell responses following all three routes of infection. Numerous skin lesions and high plasma viral loads were observed following intravenous and intradermal infection. Skin lesions peaked on day 10 and resolved by day 28 following infection. On day 28, we re-challenged all convalescent and 3 naive animals with mpox. All convalescent animals were protected against re-challenge. Transcriptomic studies showed upregulation of innate and inflammatory responses and downregulation of collagen formation and extracellular matrix organization following challenge, as well as rapid activation of T cell and plasma cell responses following re-challenge. These data suggest key mechanistic insights into mpox pathogenesis and immunity. This macaque model should prove useful for evaluating mpox vaccines and therapeutics.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37734373</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.023>10.1016/j.cell.2023.08.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37734373</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Malika Aid</dc:creator><dc:creator> Michaela Sciacca</dc:creator><dc:creator> Katherine McMahan</dc:creator><dc:creator> David Hope</dc:creator><dc:creator> Jinyan Liu</dc:creator><dc:creator> Catherine Jacob-Dolan</dc:creator><dc:creator> Olivia Powers</dc:creator><dc:creator> Julia Barrett</dc:creator><dc:creator> Cindy Wu</dc:creator><dc:creator> Audrey Mutoni</dc:creator><dc:creator> Tetyana Murdza</dc:creator><dc:creator> Hannah Richter</dc:creator><dc:creator> Jason Velasco</dc:creator><dc:creator> Elyse Teow</dc:creator><dc:creator> Mona Boursiquot</dc:creator><dc:creator> Anthony Cook</dc:creator><dc:creator> Tatyana Orekov</dc:creator><dc:creator> Melissa Hamilton</dc:creator><dc:creator> Laurent Pessaint</dc:creator><dc:creator> Alaina Ryan</dc:creator><dc:creator> Tammy Hayes</dc:creator><dc:creator> Amanda J Martinot</dc:creator><dc:creator> Michael S Seaman</dc:creator><dc:creator> Mark G Lewis</dc:creator><dc:creator> Hanne Andersen</dc:creator><dc:creator> Dan H Barouch</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Cell</dc:source><dc:title> Mpox infection protects against re-challenge in rhesus macaques</dc:title><dc:identifier> pmid:37734373</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.023</dc:identifier></item><item><title> Host traits shape virome composition and virus transmission in wild small mammals</title><link/> https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> Bats, rodents, and shrews are the most important animal sources of human infectious diseases. However, the evolution and transmission of viruses among them remain largely unexplored. Through the meta-transcriptomic sequencing of internal organ and fecal samples from 2,443 wild bats, rodents, and shrews sampled from four Chinese habitats, we identified 669 viruses, including 534 novel viruses, thereby greatly expanding the mammalian virome. Our analysis revealed high levels of phylogenetic... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14:S0092-8674(23)00916-9. doi: 10.1016/j.cell.2023.08.029. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Bats, rodents, and shrews are the most important animal sources of human infectious diseases. However, the evolution and transmission of viruses among them remain largely unexplored. Through the meta-transcriptomic sequencing of internal organ and fecal samples from 2,443 wild bats, rodents, and shrews sampled from four Chinese habitats, we identified 669 viruses, including 534 novel viruses, thereby greatly expanding the mammalian virome. Our analysis revealed high levels of phylogenetic diversity, identified cross-species virus transmission events, elucidated virus origins, and identified cases of invertebrate viruses in mammalian hosts. Host order and sample size were the most important factors impacting virome composition and patterns of virus spillover. Shrews harbored a high richness of viruses, including many invertebrate-associated viruses with multi-organ distributions, whereas rodents carried viruses with a greater capacity for host jumping. These data highlight the remarkable diversity of mammalian viruses in local habitats and their ability to emerge in new hosts.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37734372</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.029>10.1016/j.cell.2023.08.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37734372</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yan-Mei Chen</dc:creator><dc:creator> Shu-Jian Hu</dc:creator><dc:creator> Xian-Dan Lin</dc:creator><dc:creator> Jun-Hua Tian</dc:creator><dc:creator> Jia-Xin Lv</dc:creator><dc:creator> Miao-Ruo Wang</dc:creator><dc:creator> Xiu-Qi Luo</dc:creator><dc:creator> Yuan-Yuan Pei</dc:creator><dc:creator> Rui-Xue Hu</dc:creator><dc:creator> Zhi-Gang Song</dc:creator><dc:creator> Edward C Holmes</dc:creator><dc:creator> Yong-Zhen Zhang</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Cell</dc:source><dc:title> Host traits shape virome composition and virus transmission in wild small mammals</dc:title><dc:identifier> pmid:37734372</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.029</dc:identifier></item><item><title> Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates</title><link/> https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: These results demonstrate the synergistic effect of combining iPSC-derived ECs and CMs for therapy in the postmyocardial infarction heart, enabling a promising strategy toward clinical translation. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.122.061736. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Remuscularization of the mammalian heart can be achieved after cell transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). However, several hurdles remain before implementation into clinical practice. Poor survival of the implanted cells is related to insufficient vascularization, and the potential for fatal arrhythmogenesis is associated with the fetal cell-like nature of immature CMs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We generated 3 lines of hiPSC-derived endothelial cells (ECs) and hiPSC-CMs from 3 independent donors and tested hiPSC-CM sarcomeric length, gap junction protein, and calcium-handling ability in coculture with ECs. Next, we examined the therapeutic effect of the cotransplantation of hiPSC-ECs and hiPSC-CMs in NOD-SCID mice undergoing myocardial infarction (n≥4). Cardiac function was assessed by echocardiography, whereas arrhythmic events were recorded using 3-lead ECGs. We further used healthy non-human primates (n=4) with cell injection to study the cell engraftment, maturation, and integration of transplanted hiPSC-CMs, alone or along with hiPSC-ECs, by histological analysis. Last, we tested the cell therapy in ischemic reperfusion injury in non-human primates (n=4, 3, and 4 for EC+CM, CM, and control, respectively). Cardiac function was evaluated by echocardiography and cardiac MRI, whereas arrhythmic events were monitored by telemetric ECG recorders. Cell engraftment, angiogenesis, and host-graft integration of human grafts were also investigated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We demonstrated that human iPSC-ECs promote the maturity and function of hiPSC-CMs in vitro and in vivo. When cocultured with ECs, CMs showed more mature phenotypes in cellular structure and function. In the mouse model, cotransplantation augmented the EC-accompanied vascularization in the grafts, promoted the maturity of CMs at the infarct area, and improved cardiac function after myocardial infarction. Furthermore, in non-human primates, transplantation of ECs and CMs significantly enhanced graft size and vasculature and improved cardiac function after ischemic reperfusion. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These results demonstrate the synergistic effect of combining iPSC-derived ECs and CMs for therapy in the postmyocardial infarction heart, enabling a promising strategy toward clinical translation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37732466</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061736>10.1161/CIRCULATIONAHA.122.061736</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37732466</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yu-Che Cheng</dc:creator><dc:creator> Marvin L Hsieh</dc:creator><dc:creator> Chen-Ju Lin</dc:creator><dc:creator> Cindy MC Chang</dc:creator><dc:creator> Ching-Ying Huang</dc:creator><dc:creator> Riley Puntney</dc:creator><dc:creator> Amy Wu Moy</dc:creator><dc:creator> Chien-Yu Ting</dc:creator><dc:creator> Darien Zhing Herr Chan</dc:creator><dc:creator> Martin W Nicholson</dc:creator><dc:creator> Po-Ju Lin</dc:creator><dc:creator> Hung-Chih Chen</dc:creator><dc:creator> Gina C Kim</dc:creator><dc:creator> Jianhua Zhang</dc:creator><dc:creator> Jennifer Coonen</dc:creator><dc:creator> Puja Basu</dc:creator><dc:creator> Heather A Simmons</dc:creator><dc:creator> Yen-Wen Liu</dc:creator><dc:creator> Timothy A Hacker</dc:creator><dc:creator> Timothy J Kamp</dc:creator><dc:creator> Patrick CH Hsieh</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Circulation</dc:source><dc:title> Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates</dc:title><dc:identifier> pmid:37732466</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.061736</dc:identifier></item><item><title> Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III</title><link/> https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.122.060315. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation undergoing cardiac surgery. This article examines the effect of LAA occlusion on stroke reduction according to variation in the use of oral anticoagulants (OACs). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Information regarding OAC use was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks of hospital discharge, 1 and 2 years after randomization, evaluated the effect of LAA occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use. Adjusted proportional hazard modeling, with OAC use as a time-dependent covariate, was also performed to assess the effect of LAA occlusion, according to OAC use throughout the study. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: At hospital discharge, 3027 patients (63.5%) were receiving a vitamin K antagonist, and 879 (18.5%) were receiving a non-vitamin K antagonist oral anticoagulant (direct OAC), with no difference in OAC use between treatment arms. There were 2887 (60.5%) patients who received OACs at all follow-up visits, 1401 (29.4%) who received OAC at some visits, and 472 (9.9%) who never received OACs. The effect of LAA occlusion on the risk of ischemic stroke or systemic embolism was consistent after discharge across all 3 groups: hazard ratios of 0.70 (95% CI, 0.51-0.96), 0.63 (95% CI, 0.43-0.94), and 0.76 (95% CI, 0.32-1.79), respectively. An adjusted proportional hazards model with OAC use as a time-dependent covariate showed that the reduction in stroke or systemic embolism with LAA occlusion was similar whether patients were receiving OACs or not. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37732457</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.060315>10.1161/CIRCULATIONAHA.122.060315</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37732457</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Stuart J Connolly</dc:creator><dc:creator> Jeff S Healey</dc:creator><dc:creator> Emilie P Belley-Cote</dc:creator><dc:creator> Kumar Balasubramanian</dc:creator><dc:creator> Domenico Paparella</dc:creator><dc:creator> Katheryn Brady</dc:creator><dc:creator> Wilko Reents</dc:creator><dc:creator> Bernhard C Danner</dc:creator><dc:creator> PJ Devereaux</dc:creator><dc:creator> Mukul Sharma</dc:creator><dc:creator> Chinthanie Ramasundarahettige</dc:creator><dc:creator> Salim Yusuf</dc:creator><dc:creator> Richard P Whitlock</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Circulation</dc:source><dc:title> Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III</dc:title><dc:identifier> pmid:37732457</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.060315</dc:identifier></item><item><title> Existing Nongated CT Coronary Calcium Predicts Operative Risk in Patients Undergoing Noncardiac Surgeries (ENCORES)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230925160831&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Prevalence and severity of coronary calcium obtained from existing nongated chest CT imaging improve preoperative clinical risk stratification before nongated surgery. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.123.064398. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Preoperative cardiovascular risk stratification before noncardiac surgery is a common clinical challenge. Coronary artery calcium scores from ECG-gated chest computed tomography (CT) imaging are associated with perioperative events. At the time of preoperative evaluation, many patients will not have had ECG-gated CT imaging, but will have had nongated chest CT studies performed for a variety of noncardiac indications. We evaluated relationships between coronary calcium severity estimated from previous nongated chest CT imaging and perioperative major clinical events (MCE) after noncardiac surgery. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We retrospectively identified consecutive adults age ≥45 years who underwent in-hospital, major nongated surgery from 2016 to 2020 at a large academic health system composed of 4 acute care centers. All patients had nongated (contrast or noncontrast) chest CT imaging performed within 1 year before surgery. Coronary calcium in each vessel was retrospectively graded from absent to severe using a 0 to 3 scale (absent, mild, moderate, severe) by physicians blinded to clinical data. The estimated coronary calcium burden (ECCB) was computed as the sum of scores for each coronary artery (0 to 9 scale). A Revised Cardiac Risk Index was calculated for each patient. Perioperative MCE was defined as all-cause death or myocardial infarction within 30 days of surgery. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 2554 patients (median age, 68 years; 49.7% women; median Revised Cardiac Risk Index, 1) were included. The median time interval from nongated chest CT imaging to nongated surgery was 15 days (interquartile range, 3-106 days). The median ECCB was 1 (interquartile range, 0-3). Perioperative MCE occurred in 136 (5.2%) patients. Higher ECCB values were associated with stepwise increases in perioperative MCE (0: 2.9%, 1-2: 3.7%, 3-5: 8.0%; 6-9: 12.6%, <i>P</i> &lt;0.001). Addition of ECCB to a model with the Revised Cardiac Risk Index improved the C-statistic for MCE (from 0.675 to 0.712, <i>P</i> =0.018), with a net reclassification improvement of 0.428 (95% CI, 0.254-0.601, <i>P</i> &lt;0.0001). An ECCB ≥3 was associated with 2-fold higher adjusted odds of MCE versus an ECCB &lt;3 (adjusted odds ratio, 2.11 [95% CI, 1.42-3.12]). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Prevalence and severity of coronary calcium obtained from existing nongated chest CT imaging improve preoperative clinical risk stratification before nongated surgery.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230925160831&v=2.17.9.post6+86293ac">37732454</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064398>10.1161/CIRCULATIONAHA.123.064398</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37732454</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Daniel Y Choi</dc:creator><dc:creator> Dena Hayes</dc:creator><dc:creator> Samuel D Maidman</dc:creator><dc:creator> Nehal Dhaduk</dc:creator><dc:creator> Jill E Jacobs</dc:creator><dc:creator> Anna Shmukler</dc:creator><dc:creator> Jeffrey S Berger</dc:creator><dc:creator> Germaine Cuff</dc:creator><dc:creator> David Rehe</dc:creator><dc:creator> Mitchell Lee</dc:creator><dc:creator> Robert Donnino</dc:creator><dc:creator> Nathaniel R Smilowitz</dc:creator><dc:date> 2023-09-21</dc:date><dc:source> Circulation</dc:source><dc:title> Existing Nongated CT Coronary Calcium Predicts Operative Risk in Patients Undergoing Noncardiac Surgeries (ENCORES)</dc:title><dc:identifier> pmid:37732454</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064398</dc:identifier></item></channel></rss>